Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics.

It is estimated that 70 per cent of people in care homes have dementia or severe memory problems. More than 25,000 people from Black, Asian and minority ethnic groups in the UK are affected by ...